Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (Opti-Q)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01918397
Recruitment Status : Active, not recruiting
First Posted : August 7, 2013
Last Update Posted : March 20, 2019
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Centers for Disease Control and Prevention
Macleods Pharmaceuticals, Ltd
Information provided by (Responsible Party):
Charles R Horsburgh, Boston University

Tracking Information
First Submitted Date  ICMJE August 5, 2013
First Posted Date  ICMJE August 7, 2013
Last Update Posted Date March 20, 2019
Actual Study Start Date  ICMJE January 2015
Estimated Primary Completion Date March 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 28, 2018)
  • Treatment Efficacy [ Time Frame: 28 weeks ]
    The primary efficacy endpoint is the time to sputum culture conversion from positive to negative for M. tuberculosis growth on solid medium. This is defined as the time from initiation of study treatment to the first of two successive negative cultures one study visit apart that are not followed by a culture-positive specimen within 28 weeks of treatment initiation. To ensure that each subject will be evaluable for the primary endpoint, bi-weekly sputum cultures will be collected for 12 weeks, then every 4 weeks through 24 weeks of treatment.
  • Treatment Safety [ Time Frame: 28 weeks ]
    The primary safety endpoint will be the number of grade 3, 4 and 5 adverse events (AEs), occurring up to and including the time on study drug plus four weeks post study drug completion.
Original Primary Outcome Measures  ICMJE
 (submitted: August 5, 2013)
Efficacy [ Time Frame: 28 weeks ]
The primary efficacy endpoint is the time to sputum culture conversion from positive to negative for M. tuberculosis growth on solid medium. This is defined as the time from initiation of study treatment to the first of two successive negative cultures one study visit apart that are not followed by a culture-positive specimen within 28 weeks of treatment initiation. To ensure that each subject will be evaluable for the primary endpoint, bi-weekly sputum cultures will be collected for 12 weeks, then every 4 weeks through 24 weeks of treatment.
Change History Complete list of historical versions of study NCT01918397 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 28, 2018)
Treatment Tolerability [ Time Frame: 24 weeks ]
The primary endpoint for the analysis of tolerability will be the ability to complete 24 weeks of treatment with the assigned levofloxacin dose (in mg/kg at enrollment).
Original Secondary Outcome Measures  ICMJE
 (submitted: August 5, 2013)
Safety [ Time Frame: 28 weeks ]
The primary safety endpoint will be the number of grade 3, 4 and 5 adverse events (AEs), occurring up to and including the time on study drug plus four weeks post study drug completion.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: August 5, 2013)
Tolerability [ Time Frame: 24 weeks ]
The primary endpoint for the analysis of tolerability will be the ability to complete 24 weeks of treatment with the assigned levofloxacin dose (in mg/kg at enrollment).
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Official Title  ICMJE Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
Brief Summary Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around the world. This type of tuberculosis is very difficult to treat, and many patients die from it. Drugs of the fluoroquinolone class are very important for treating MDR-TB, but the best dose of one of the most effective fluoroquinolones, levofloxacin, is not known. This application proposes a study to determine the best dose of levofloxacin to use in treating MDR-TB. 120 patients will receive their usual treatment, plus levofloxacin at one of four doses. The study will be performed in Peru and in South Africa, where MDR-TB is common.
Detailed Description

MDR-TB is a growing threat to international health. A recent report from WHO estimated that over 440,000 new cases of MDR-TB occurred in 127 countries in 2008, causing 150,000 deaths; this represents a 55% increase in the number of cases since 2000. Current treatment regimens have only a 58-67% success rate, and as many as 20% of those who fail to respond to treatment die of tuberculosis; those who do not die become chronic carriers and spread MDR-TB to others.

Fluoroquinolones (FQ) are an essential part of regimens for the treatment of MDR-TB; substantially better outcomes have consistently been seen in patients with MDR-TB who are treated with FQ, and newer FQ (levofloxacin, gatifloxacin and moxifloxacin) are the most potent antituberculosis agents available for MDR-TB treatment. However, gatifloxacin has been taken off the market because of dysglycemic reactions and moxifloxacin produces marked QT prolongation, increasing risk of fatal arrhythmia. In contrast, QT studies of levofloxacin have found minimal prolongation at doses up to 20mg/kg. Levofloxacin is currently given for TB at doses of 11-14 mg/kg/day and has been well tolerated at doses up to 20 mg/kg. Although the efficacy of levofloxacin increases as exposure increases both in animal studies of TB and in human studies of gram-negative bacteria, its efficacy at higher doses against TB in humans has not been studied. Thus, determination of the most efficacious and well-tolerated dose of levofloxacin is an important research priority. In this Phase 2 study, we will determine the levofloxacin dose and exposure that achieve the greatest reduction in mycobacterial burden with acceptable tolerability by studying 120 adults with smear- and culture-positive pulmonary MDR-TB at sites in Peru and South Africa. Levofloxacin will be administered with an optimized background regimen (OBR) to address the following Specific

Aims:

Specific Aim 1: To determine the levofloxacin AUC/MIC that provides the shortest time to sputum culture conversion in solid medium.

Specific Aim 2: To determine the highest levofloxacin AUC that is both safe and associated with fewer than 25% of patients discontinuing or reducing their dose of levofloxacin.

Specific Aim 3: To develop a dosing algorithm to achieve the levofloxacin AUC associated with maximal efficacy and acceptable safety/tolerability.

This clinical trial will increase our ability to cure MDR-TB and prevent the emergence of resistance to new TB drug classes by optimizing dosing and improving the effectiveness of an existing antimycobacterial agent, using a novel and versatile study design which more rapidly and efficiently identifies advances in this critical area. Construction of an algorithm to predict the optimal levofloxacin dose will allow more effective use of levofloxacin, particularly in areas with limited resources, where the burden of MDR-TB is the greatest.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Tuberculosis, Multidrug-Resistant
Intervention  ICMJE
  • Drug: Levofloxacin
    Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate.
    Other Name: Levaquin, Quixin, and Iquix
  • Drug: Optimized background regimen (OBR)
    For this study "OBR" will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses.
Study Arms  ICMJE
  • Active Comparator: Dose 1
    Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
    Interventions:
    • Drug: Levofloxacin
    • Drug: Optimized background regimen (OBR)
  • Experimental: Dose 2
    Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
    Interventions:
    • Drug: Levofloxacin
    • Drug: Optimized background regimen (OBR)
  • Experimental: Dose 3
    Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
    Interventions:
    • Drug: Levofloxacin
    • Drug: Optimized background regimen (OBR)
  • Experimental: Dose 4
    Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
    Interventions:
    • Drug: Levofloxacin
    • Drug: Optimized background regimen (OBR)
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: February 13, 2017)
111
Original Estimated Enrollment  ICMJE
 (submitted: August 5, 2013)
100
Estimated Study Completion Date  ICMJE March 2020
Estimated Primary Completion Date March 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients with smear-positive, culture positive* pulmonary TB
  2. Sputum contains isoniazid* and rifampin-resistant, Ofloxacin-susceptible MTB, all by MTBDR-sl
  3. Previously treated or newly diagnosed with tuberculosis
  4. Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 3 months prior to enrollment.
  5. Age ≥ 18 years.
  6. Weight > 40 Kg
  7. Karnofsky score of > 60 (see section 18.1)
  8. Willingness by the patient to attend scheduled follow-up visits and undergo study assessments.
  9. Women with child-bearing potential must agree to use birth control if you are having sex with men while participating in this study and for three months afterward.
  10. Laboratory parameters (performed within 14 days prior to enrollment):

    • Estimated Serum creatinine clearance should be <50, using nomogram78
    • Hemoglobin concentration ≥ 9.0 g/dL
    • Platelet count of ≥ 80,000/mm3
    • Absolute neutrophil count (ANC) > 1000/ mm3
    • Negative pregnancy test (for women of childbearing potential) within 14 days of enrollment
    • HIV viral load and CD4 count if HIV infected (within 3 months)
    • Serum ALT and total bilirubin <3 times upper limit of normal
  11. Able to provide informed consent

Note: *Subjects may be enrolled on the basis of a presumption that they will be culture positive at either screening or baseline if they are smear-positive, but they will be excluded from the analysis if cultures are subsequently negative. This will not be deemed a protocol violation. Similarly, subjects with rifampin susceptibility on a DNA-based test may be enrolled on the basis of a presumption that they will also be INH-resistant, but they will be excluded from the analysis if the isolate is subsequently shown to be INH-susceptible. This will also not be deemed a protocol violation.

Exclusion Criteria:

  1. Currently breast-feeding or pregnant.
  2. Known allergy or intolerance to or toxicity from fluoroquinolones or other medications utilized in this study.
  3. In the judgment of the physician the patient is not expected to survive for 6 months
  4. Anticipated surgical intervention for the treatment of pulmonary tuberculosis
  5. Participation in another investigational drug trial within the past 30 days
  6. Concurrent use of known QT-prolonging drugs: a list of such medications can be found at http://www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm
  7. Poorly controlled diabetes
  8. Known g-6-phosphate dehydrogenase deficiency
  9. Use of quinolone for 7 days within past 30 days
  10. QTc interval greater than 450 msec for men or greater than 470 msec for women
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Peru,   South Africa
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01918397
Other Study ID Numbers  ICMJE H-32150
1U01AI100805-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Charles R Horsburgh, Boston University
Study Sponsor  ICMJE Boston University
Collaborators  ICMJE
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Centers for Disease Control and Prevention
  • Macleods Pharmaceuticals, Ltd
Investigators  ICMJE
Principal Investigator: Charles R Horsburgh, MD Boston University
PRS Account Boston University
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP